scholarly journals A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo

2017 ◽  
Vol 76 (1) ◽  
pp. 150-151.e3 ◽  
Author(s):  
Stefan G. Vanderweil ◽  
Shinya Amano ◽  
Wei-Che Ko ◽  
Jillian M. Richmond ◽  
Michelle Kelley ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Phase Ii ◽  
Phase Ii Clinical Trial ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals The Efficacy and Safety of Shen Guo Lao Nian Granule for Common Cold of Qi-Deficiency Syndrome: Study Protocol for a Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase II Clinical Trial

2017 ◽  
Vol 2017 ◽  
pp. 1-11
Author(s):  
Xuemei Liu ◽  
Juanjuan Fu ◽  
Tao Fan ◽  
Wei Liu ◽  
Hongli Jiang ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Phase Ii ◽  
Study Protocol ◽  
Common Cold ◽  
Dose Group ◽  
Deficiency Syndrome ◽  
Phase Ii Clinical Trial ◽  
High Dose ◽  
Double Blind ◽  
Double Blind Placebo

Background. Common cold is one of the most frequently occurring illnesses in primary healthcare services and represents considerable disease burden. Common cold of Qi-deficiency syndrome (CCQDS) is an important but less addressed traditional Chinese medicine (TCM) pattern. We designed a protocol to explore the efficacy, safety, and optimal dose of Shen Guo Lao Nian Granule (SGLNG) for treating CCQDS. Methods/Design. This is a multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. A total of 240 eligible patients will be recruited from five centers. Patients are randomly assigned to high-dose group, middle-dose group, low-dose group, or control group in a 1 : 1 : 1 : 1 ratio. All drugs are required to be taken 3 times daily for 5 days with a 5-day follow-up period. Primary outcomes are duration of all symptoms, total score reduction on Jackson’s scale, and TCM symptoms scale. Secondary outcomes include every single TCM symptom duration and score reduction, TCM main symptoms disappearance rate, curative effects, and comparison between Jackson’s scale and TCM symptom scale. Ethics and Trial Registration. This study protocol was approved by the Ethics Committee of Clinical Trials and Biomedicine of West China Hospital of Sichuan University (number IRB-2014-12) and registered with the Chinese Clinical Trial Registry (ChiCTR-IPR-15006349).

scholarly journals A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology

2014 ◽  
Vol 7 (5) ◽  
pp. 496-504 ◽  
Author(s):  
Kenneth G. Linden ◽  
Sancy A. Leachman ◽  
Jonathan S. Zager ◽  
James G. Jakowatz ◽  
Jaye L. Viner ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Phase Ii ◽  
Phase Ii Clinical Trial ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial on the Use of Uncaria tomentosa (Cat's Claw) for Aromatase Inhibitor-Induced Arthralgia: A Pilot Study

2019 ◽  
Vol 19 (1) ◽  
pp. 24-31
Author(s):  
Renan Sordi ◽  
Suellen Nastri Castro ◽  
Andrea Thaumaturgo Lera ◽  
Macilon Nonato Irene ◽  
Marilia de Melo Farinazzo ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Pilot Study ◽  
Aromatase Inhibitor ◽  
Phase Ii ◽  
Phase Ii Clinical Trial ◽  
Double Blind ◽  
Uncaria Tomentosa ◽  
Double Blind Placebo
Sign in / Sign up

Export Citation Format

Share Document